Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations
Inga Hofmann(Dana-Farber Cancer Institute), Leslie Lehmann(Harvard University), Dongjing Guo(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Hasan Al‐Sayegh(Sultan Qaboos University), Alyssa Stetson(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Serine Avagyan(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Wendy B. London(Dana-Farber Cancer Institute)
Cited by 35
Related Papers
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy
|Nature Genetics|2015|367
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure
|Blood|2016|333
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|237